Search
Search Results
-
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
BackgroundThe prognostic impact of immune-related adverse events during immune checkpoint inhibitor-based combination therapy for advanced renal cell...
-
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Purpose of ReviewImmune checkpoint inhibitor (ICI) therapy has emerged as a pivotal advancement in cancer treatment, but the widespread adoption has...
-
Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis
Purpose of ReviewImmune checkpoint inhibitors (ICI) have revolutionized cancer care and work primarily by blocking CTLA-4 (cytotoxic...
-
Update on Immune Checkpoint Inhibitor Enterocolitis
Purpose of ReviewImmune checkpoint inhibitor (ICI) therapy revolutionized the treatment of multiple solid and hematologic malignancies. Yet, with it...
-
Sclerosing mesenteritis following immune checkpoint inhibitor therapy
PurposeSclerosing mesenteritis (SM), a fibroinflammatory process of the mesentery, can rarely occur after immune checkpoint inhibitor (ICI) therapy;...
-
Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery
PurposeAdvances in primary lung cancer drug therapy have extended patients’ survival, including patients with stage IV disease. This study assessed...
-
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Antiangiogenic agents, generally antibodies or tyrosine-kinase inhibitors that target the VEGF–VEGFR pathway, are currently among the few combination...
-
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint inhibitors (ICIs) have become an essential part of treatment for many cancer types. These monoclonal antibodies remove a critical...
-
Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis
PurposeImmune checkpoint inhibitors (ICIs) are of great success in cancer therapy. This study aimed to identify adrenal insufficiency (AI) associated...
-
Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives
Metastatic gastric and gastroesophageal junction cancers have been treated with chemotherapy, but the landscape of cancer treatment is rapidly...
-
Update on Immune Checkpoint Inhibitor-Associated Uveitis
Purpose of ReviewIn this article, we review the current updates on immune checkpoint inhibitors (ICPIs) and the management of ICPI-associated uveitis.
...
-
The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in humans, which is prone to recurrence and metastasis and has a poor...
-
The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study
BackgroundThe real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or...
-
Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice
BackgroundCancer immunotherapy aims to unleash the immune system’s potential against cancer cells, providing sustained relief for tumors responsive...
-
Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event
IntroductionT cell activation can lead to osteoporosis and while there are several case reports of fractures occurring after immune checkpoint...
-
Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis
Purpose of ReviewImmune checkpoint inhibitor (ICI)-related myocarditis poses a major clinical challenge given its non-specific presentation, rapid...
-
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours
Purpose of ReviewThe goal of this review was to examine the role and practical applications of integrative oncology strategies in supporting immune...
-
Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases
Immune checkpoint inhibitor (ICI) therapies carry the risk of major immune-related adverse events (irAEs). Among the most severe irAEs is epidermal...
-
Immune checkpoint inhibitors-induced diabetes mellitus (review)
Immune checkpoint inhibitors (ICIs) have become extensively utilized in the early-stage treatment of various cancers, offering additional therapeutic...
-
Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features
Immune checkpoint inhibitors are a very promising novel class of immune response-regulating drugs for cancer treatment. Hypophysitis is one of their...
